Doximity reports news about its digital platform for U.S. medical professionals, including tools for clinical collaboration, medical news and research, career and on-call management, documentation workflows, and virtual patient visits. Company updates commonly cover quarterly financial results, platform engagement, workflow products, and AI-powered clinical reference and search capabilities.
Recurring developments also include Doximity Dialer telehealth recognition, physician research on AI adoption, and the integration of Pathway Medical into Doximity's clinical reference offerings. The company's news flow links product expansion with its verified medical-professional network and its role in digital workflow tools built for physicians.
Doximity (NYSE: DOCS) reported fiscal 2027 second-quarter revenue of $174.5 million, up 4% year over year, as earnings declined. For the quarter ended September 30, 2026, net income fell to $34.7 million from $62.1 million, and diluted earnings per share fell to $0.18 from $0.31. Net income margin narrowed to 19.9% from 36.8%. Adjusted EBITDA, a measure of earnings excluding certain expenses, declined 12% to $88.9 million; its margin fell to 50.9% from 59.8%.
Operating cash flow was $93.3 million, down 1%; free cash flow was $91.3 million, down less than 1%. Doximity expects third-quarter revenue of $195 million–$196 million and adjusted EBITDA of $102.5 million–$103.5 million. Updated fiscal 2027 guidance calls for revenue of $678 million–$683 million and adjusted EBITDA of $317 million–$325 million. More than 190 health systems have purchased its AI suite.
Doximity (NYSE: DOCS) has launched DoseCheck, a free medication-dosing verification tool available to all Doximity Ask users on mobile and desktop. It checks AI-generated dosing claims against a structured drug database using FDA labeling and professional guidelines.
Doximity says DoseCheck reduces dosing errors by more than 99%. Its testing of nine widely used AI models with more than 8,000 dosing questions based on physician queries found that at least 2.3% of dosing claims were wrong; 43.8% of detected errors were serious or potentially lethal. These findings describe the tested models, not DoseCheck's remaining error rate.
Doximity (DOCS) and Wolters Kluwer Health signed a partnership to bring UpToDate clinical content directly into Doximity Ask.
In the coming weeks, clinicians at health systems using Doximity and UpToDate will see answers based on UpToDate content alongside Ask’s AI-generated answer. UpToDate covers 13,000 topics and best practice guides and draws on 7,600 expert clinicians, editors and peer reviewers who regularly review clinical, drug and patient content.
Doximity’s Clinical AI Suite, which includes Ask, has been deployed across more than 165 health systems, including 10 of the nation’s top 20 hospitals. Its PeerCheck program features more than 12,000 cited physician experts evaluating and improving Ask outputs. Doximity’s membership includes more than 85% of U.S. doctors.
Doximity (NYSE:DOCS) will release its fiscal 2027 second-quarter financial results after market close on November 5, 2026.
The quarter ended September 30, 2026. A conference call and webcast to discuss the results will begin at 2:00 p.m. PT (5:00 p.m. ET) that day. A webcast replay will be available on the company’s investor relations website afterward.
Doximity (NYSE: DOCS) has extended its 13-year partnership with U.S. News & World Report to support hospital rankings and patient-care tools.
Doximity will remain the exclusive third-party provider of the Expert Opinion physician survey used in U.S. News' Best Hospitals and Best Children's Hospitals rankings. It will also continue supplying physician profile data for Doctor Finder, which helps patients find physicians and book appointments with U.S. News hospital partners directly from the site. Through Patient Connect, Doximity will continue enabling appointment booking for those hospital partners.
The agreement maintains Doximity's role in U.S. News' physician- and hospital-facing products. U.S. News says more than 65 million people use its site each year.
Doximity (DOCS) has been named a founding partner and leading clinical AI benchmark contributor in Fireworks’ new Specialized Intelligence Index of domain-specific AI evaluations.
As part of the launch, Doximity is releasing Bedside Bench, an open-source benchmark designed to test whether clinical AI can act as a trusted bedside partner to physicians using realistic clinical scenarios rather than multiple-choice questions. The benchmark evaluates areas such as drug safety, correct use of guideline and trial evidence, health-equity and bias issues, and the ability to choose appropriate actions from many options.
When independently graded by Fireworks, Doximity Ask ranked first versus frontier models, following its top performance among U.S.-based models in July’s NOHARM study from Stanford and Harvard researchers.
Doximity (NYSE: DOCS) released its 2026 Physician Compensation Report, showing that many U.S. physicians now view AI skills as a path to higher pay. 23% expect AI to raise their compensation within 12 months, and 67% believe AI-proficient physicians will gain a meaningful earnings edge over non-users.
The report finds AI is entering staffing decisions: 39% said AI proficiency already factors into hiring and promotion, with 15% calling it a major or moderate factor. At the same time, workforce strain remains severe: 85% said the physician shortage has affected their practice, and 76% felt it compromised care quality in the past year. In a June 2026 poll, 82% reported being overworked; among them, 66% are considering a career change and 46% are eyeing early retirement.
Average physician pay rose 2% in 2025, below the prior year’s 3.7%. The gender pay gap held at 26%, with men earning about $122,276 more, while surgical specialists earned 90.1% more than primary care physicians. Findings draw on over 23,000 compensation responses from Doximity’s network, which includes more than 85% of U.S. physicians.
Doximity (NYSE: DOCS) reported fiscal 2027 Q1 revenue of $156.6 million, up 7% year-over-year, for the quarter ended June 30, 2026. Net income was $24.3 million with a 15.5% margin, while non-GAAP net income reached $55.0 million, a 35.1% margin. Adjusted EBITDA was $74.8 million, down 6% year-over-year, with a 47.7% margin.
Operating cash flow was $42.0 million and free cash flow $39.6 million, both declining over 30% year-over-year. Doximity ended the quarter with $273.6 million in cash and equivalents and $414.2 million in marketable securities. The company guided Q2 revenue to $170–171 million and full-year fiscal 2027 revenue to $671–681 million, with adjusted EBITDA guidance of $80.5–81.5 million for Q2 and $309–329 million for the year.
Doximity (NYSE:DOCS) announced it will release financial results for its fiscal first quarter ended June 30, 2026, after market close on August 6, 2026. The company will host a conference call and live webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results, with access and replay available via its Investor Relations website.
Doximity (NYSE: DOCS) reported that its HIPAA-compliant clinical AI platform, Doximity Ask, ranked first on the real-world clinical sample of the independent NOHARM safety benchmark, outperforming OpenEvidence, GPT-5.6 Sol, Claude Fable 5 and other frontier models.
The NOHARM study was conducted by ARISE, a clinical AI research team led by physicians from Stanford and Harvard medical schools, using simulated patient cases. According to Doximity, Ask’s performance is linked to extensive physician authorship via its PeerCheck program, where more than 11,000 cited physician experts have reviewed and refined outputs. Doximity’s Clinical AI Suite has been reviewed, approved and deployed across over 150 health systems, including 8 of the top 20 U.S. hospitals, and incorporates end-to-end encryption, role-based access controls, audit logging and session isolation.